Brazil represents the largest medical device and pharmaceutical marketplace in Latin America, serving as a premier destination for global clinical trials due to its diverse patient population and sophisticated medical infrastructure. However, navigating the country’s regulatory landscape requires strict adherence to the National Health Surveillance Agency (ANVISA). Missing local nuances can stall international drug pipelines for months.
Deploying specialized end-to-end clinical trial &
CRO services in Brazil bridges the gap between global protocol designs and local operational compliance.
1
